Immunocore Announced KIMMTRAK Demonstrated Long-Term Survival Benefit In HLA-A*02:01 Positive Patients With Previously Untreated Metastatic Uveal Melanoma
Portfolio Pulse from Charles Gross
Immunocore Holdings plc (NASDAQ:IMCR) announced that the three-year overall survival data from the KIMMTRAK Phase 3 trial in previously untreated HLA-A*02:01 positive patients with metastatic uveal melanoma has been published in The New England Journal of Medicine. The data was also presented at the European Society for Medical Oncology (ESMO) Congress 2023. KIMMTRAK demonstrated long-term survival benefit in these patients.
October 21, 2023 | 1:25 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Immunocore's KIMMTRAK has shown long-term survival benefits in a Phase 3 trial for metastatic uveal melanoma patients. This positive data, published in a prestigious journal and presented at a major conference, could boost investor confidence in the company.
The publication of positive Phase 3 trial results in a prestigious medical journal and the presentation at a major medical conference increases the visibility and credibility of Immunocore's KIMMTRAK. This could lead to increased investor confidence in the company and potentially a rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100